As a physiologist, Dr. Bailey-Downs has a strong background in redox biology, pharmaceutical research, and in vivo disease modeling. In addition to her research, she has extensive experience in contract establishment and grant administration. She is currently coordinating the administrative and infrastructural requirements for the newly established Center for Pregnancy & Newborn Research.
PhD - University of Oklahoma Health Sciences Center
Postdoctoral Fellowship - DormaTarg
Dr. Bailey-Downs’ early research with ROCA (Reynolds Oklahoma Center on Aging) focused on age-associated vascular dysfunction due to perturbations in IGF-1-modulated Nrf2 response to oxidative insults. She gained years of experience in nonclinical small molecule drug development, formulation, and efficacy evaluation in vitro and in vivo while working in the biotechnology sector. She developed and tested immunocompetent syngeneic mouse models and evaluated numerous drug delivery methods. Dr. Bailey-Downs now applies her knowledge of disease modeling, pharmaceutics, and redox biology to understand molecular pathways underlying cardiopulmonary & vascular pathologies associated with prematurity.
- Steyn FJ, Ngo ST, Chen VP, Bailey-Downs LC, Xie TY, Ghadami M, Brimijoin S, Freeman WM, Rubinstein M, Low MJ, Stout MB. 17α-estradiol acts through hypothalamic pro-opiomelanocortin expressing neurons to reduce feeding behavior. Aging Cell. 2018 Feb;17(1).
- Ziegler J, Bastian A, Lerner M, Bailey-Downs L, Saunders D, Smith N, Sutton J, Battiste JD, Ihnat MA, Gangjee A, Towner RA. AG488 as a therapy against gliomas. Oncotarget. 2017 Sep 22;8(42):71833-71844.
- Hurst RE, Bastian A, Bailey-Downs L, Ihnat MA. Targeting dormant micrometastases: rationale, evidence to date and clinical implications. Ther Adv Med Oncol. 2016 Mar;8(2):126-37.